A Comprehensive Monograph on Nilutamide (DB00665): From Clinical Utility to Therapeutic Obsolescence

Executive Summary and Drug Identification

Nilutamide is a pure, nonsteroidal antiandrogen (NSAA) that functions as a competitive antagonist of the androgen receptor (AR). As a first-generation agent in its class, it was developed to provide a more targeted approach to hormone therapy for androgen-sensitive malignancies. Its primary approved indication is for the treatment of metastatic prostate cancer, where it is used in combination with surgical castration to achieve a state of maximal androgen blockade (MAB). The therapeutic rationale is to block the effects of residual androgens, primarily of adrenal origin, that are not eliminated by orchiectomy. Despite this clear mechanism of action, the clinical utility of Nilutamide is severely limited by a distinct and unfavorable safety profile. This profile is characterized by risks of potentially fatal interstitial pneumonitis and significant hepatotoxicity, which necessitate rigorous patient monitoring. Furthermore, Nilutamide is associated with a unique constellation of side effects, including impaired dark adaptation and a disulfiram-like alcohol intolerance, which can significantly impact patient quality of life. These substantial risks, coupled with the development of better-tolerated and more potent agents like bicalutamide and subsequent second-generation antiandrogens, have rendered Nilutamide largely obsolete in modern clinical practice.[1] It now serves primarily as a subject of historical and pharmacological interest, illustrating the evolution of androgen receptor-targeted therapies.

Identifier	Details	Source(s)
Generic Name	Nilutamide	4
Brand Names	Nilandron, Anandron	1
DrugBank ID	DB00665	4
CAS Number	63612-50-0	7
Type	Small Molecule	4
Chemical Class	Imidazolidinone, (Trifluoromethyl)benzene, C-nitro compound	9
Pharmacological Class	Antiandrogen, Antineoplastic Agent, Androgen Receptor Inhibitor	9
ATC Code	L02BB02 (Anti-androgens)	9
Alternative Names/Codes	RU-23908, RU 23908	11

Chemical Profile and Pharmaceutical Formulation

The molecular and physical characteristics of Nilutamide define its biological activity, formulation, and, critically, its toxicity profile. As a synthetic compound, its structure was designed to interact specifically with the androgen receptor while avoiding the steroidal backbone of earlier hormonal agents.

Chemical Structure and Nomenclature

Nilutamide is a synthetic, nonsteroidal compound belonging to the imidazolidinone chemical class. Its systematic IUPAC name is 5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione.[9] The molecule's architecture is composed of two primary moieties: a central imidazolidinedione heterocyclic ring and a substituted phenyl ring attached to one of the ring's nitrogen atoms. The phenyl ring is critically substituted with two electron-withdrawing groups: a nitro group (

NO2​) at the para-position (position 4) and a trifluoromethyl group (CF3​) at the meta-position (position 3) relative to the point of attachment.[9]

The structural formula is as follows:

This specific arrangement of functional groups is fundamental to its pharmacological activity. However, the presence of the nitro group is a crucial structural feature that has been mechanistically implicated in the drug's two most severe organ toxicities: hepatotoxicity and interstitial pneumonitis. The metabolism of aromatic nitro compounds can generate reactive intermediates that induce oxidative stress and cellular damage. This direct link between a specific chemical moiety and a distinct clinical toxicity profile provides a compelling explanation for Nilutamide's unfavorable safety record compared to other antiandrogens that lack this functional group, and it underscores the importance of structure-activity and structure-toxicity relationships in drug design.[1]

Physical and Chemical Properties

Nilutamide presents as a microcrystalline, white to practically white powder.[13] Its key physicochemical properties are summarized below:

• Molecular Formula: C12​H10​F3​N3​O4​ [13]
• Molecular Weight: The calculated molecular weight is approximately 317.22 to 317.25 g/mol.[13]
• Solubility: It exhibits poor aqueous solubility, being only slightly soluble in water at less than 0.1% weight/volume at 25°C. In contrast, it is freely soluble in a range of organic solvents, including ethyl acetate, acetone, chloroform, ethyl alcohol, dichloromethane, and methanol.[13] This lipophilic character facilitates its absorption and distribution, including its ability to cross the blood-brain barrier.[1]
• Melting Point: The melting point of Nilutamide is reported to be in the range of 153°C to 157°C.[15]

Pharmaceutical Formulation

Nilutamide is formulated for oral administration, reflecting its high bioavailability when taken by this route.

• Available Forms: The medication is manufactured in the form of oral tablets. Commercially, it has been available in strengths of 50 mg and 150 mg.[1]
• Excipients: In addition to the active pharmaceutical ingredient, Nilutamide tablets contain several inactive ingredients (excipients) that aid in the manufacturing process and ensure tablet stability and proper dissolution. These commonly include corn starch, lactose, povidone, docusate sodium, magnesium stearate, and talc.[16] The presence of lactose may be a consideration for patients with severe lactose intolerance.

Comprehensive Pharmacology

The pharmacological profile of Nilutamide is defined by its highly specific interaction with the androgen receptor and its distinct pharmacokinetic properties. A thorough understanding of its mechanism, pharmacodynamics, and the body's handling of the drug is essential to appreciate both its therapeutic effect and its significant limitations.

Mechanism of Action

Nilutamide is classified as a pure, selective, nonsteroidal antiandrogen.[4] Its therapeutic effect is derived from its function as a direct and competitive antagonist at the ligand-binding domain of the androgen receptor (AR).[1] In androgen-sensitive tissues like the prostate, cell growth and function are driven by the binding of endogenous androgens—primarily testosterone and its more potent intracellular metabolite, dihydrotestosterone (DHT)—to the AR.[1]

The mechanism of Nilutamide involves the following steps:

1. Competitive Binding: Nilutamide competes with testosterone and DHT for the binding site on the AR. By occupying this site, it physically prevents the natural hormones from binding and activating the receptor.[4]
2. Inhibition of Conformational Change: The binding of an agonist (like DHT) normally induces a critical conformational change in the AR. This change is necessary for the dissociation of heat shock proteins, receptor dimerization, and subsequent translocation from the cytoplasm into the cell nucleus. Nilutamide, as an antagonist, binds to the receptor but fails to induce this activating conformational change, effectively locking the receptor in an inactive state.[20]
3. Blockade of Gene Transcription: Because the AR remains inactive and is prevented from translocating to the nucleus, it cannot bind to specific DNA sequences known as androgen response elements (AREs) in the promoter regions of target genes. This blockade prevents the transcription of androgen-dependent genes that are essential for the growth, proliferation, and survival of prostate cells.[4]

By interrupting this critical signaling pathway, Nilutamide effectively inhibits the hormonal stimulus driving the growth of both normal and malignant prostatic tissue.[4]

Pharmacodynamics

The pharmacodynamic properties of Nilutamide describe its effects on the body at a molecular and systemic level.

• Receptor Specificity: A key feature of Nilutamide is its high specificity. It demonstrates a strong affinity for the androgen receptor but lacks any significant binding or functional activity at other steroid hormone receptors, including progestogen, estrogen, mineralocorticoid, and glucocorticoid receptors. This selectivity is what defines it as a "pure" antiandrogen, distinguishing it from steroidal agents like cyproterone acetate, which may have progestogenic or other hormonal activities.[4]
• Binding Affinity: In comparative terms, the relative binding affinity of Nilutamide for the AR is considered similar to that of hydroxyflutamide (the active metabolite of its predecessor, flutamide) but is notably lower than that of its successor, bicalutamide.[4]
• Hormonal Feedback Loop: When administered as a monotherapy, Nilutamide's peripheral blockade of the AR prevents androgens from exerting their normal negative feedback effect on the hypothalamic-pituitary-gonadal (HPG) axis. The hypothalamus and pituitary gland perceive a state of androgen deficiency, leading to an increased release of gonadotropin-releasing hormone (GnRH) and, subsequently, luteinizing hormone (LH). The elevated LH stimulates the Leydig cells in the testes to increase production of testosterone. This rise in circulating testosterone can then be converted to estradiol via aromatase, leading to increased estrogen levels as well.[1] This physiological response explains why Nilutamide is ineffective and not indicated as a monotherapy for prostate cancer, as the surge in testosterone would eventually overwhelm the receptor blockade. It must be combined with a method of androgen deprivation (surgical or medical castration) that ablates testicular testosterone production, thereby breaking this feedback loop.[1] This very pharmacodynamic effect, however, was the basis for its investigational use in feminizing hormone therapy, where the dual action of blocking testosterone's effects while simultaneously increasing estradiol levels was seen as a potential therapeutic advantage, albeit one that was ultimately outweighed by safety concerns and the availability of better options.[1]
• Mitochondrial Toxicity: Beyond its effects on the AR, Nilutamide has been demonstrated to exert direct cellular toxicity. Similar to flutamide, it can inhibit the function of respiratory complex I (NADH ubiquinone oxidoreductase) within the mitochondrial electron transport chain. This impairment disrupts cellular energy production (ATP synthesis) and can lead to the generation of reactive oxygen species, inducing oxidative stress. This mechanism is considered a plausible explanation for the drug's observed hepatotoxicity.[1]

Pharmacokinetics

The pharmacokinetic profile of Nilutamide—its absorption, distribution, metabolism, and excretion (ADME)—dictates its dosing regimen and has important implications for its safety.

• Absorption: Following oral administration, Nilutamide is rapidly and completely absorbed from the gastrointestinal tract. This results in high and sustained plasma concentrations. The absorption is not significantly affected by the presence of food, allowing it to be taken with or without meals.[4]
• Distribution: Nilutamide is moderately bound to plasma proteins, with a protein binding percentage of approximately 84%. It exhibits low binding to erythrocytes. This binding is non-saturable, meaning its pharmacokinetics remain linear across the therapeutic dose range.[10] Due to its lipophilicity, it is able to cross the blood-brain barrier and exert central antiandrogenic actions.[1]
• Metabolism: The drug undergoes extensive hepatic metabolism, primarily mediated by the cytochrome P-450 (CYP) enzyme system. Consequently, less than 2% of the parent drug is excreted unchanged in the urine. At least five metabolites have been identified in human urine. One of these metabolites is pharmacologically active, possessing between 25% and 50% of the antiandrogenic activity of the parent compound. The pharmacokinetics of these metabolites have not been fully characterized.[4]
• Excretion: Elimination of Nilutamide and its metabolites occurs predominantly via the kidneys. Approximately 62% of an administered dose is recovered in the urine within the first 120 hours. Fecal elimination is a minor route, accounting for only 1.4% to 7% of the dose. The elimination process is slow, likely continuing beyond five days after a single dose.[4]
• Half-Life: Nilutamide possesses a long elimination half-life, typically ranging from 38 to 59 hours, with an average of 41 to 49 hours.[4] This extended half-life is advantageous from a clinical perspective, as it allows for a convenient once-daily dosing regimen, a clear improvement over the three-times-daily dosing required for flutamide.[25] However, this pharmacokinetic property becomes a significant liability in the context of toxicity. Should a patient develop a severe adverse reaction such as interstitial pneumonitis or fulminant hepatitis, the long half-life means that the offending drug will persist in the system for a prolonged period (approximately 8-10 days for near-complete clearance) even after administration has been stopped. This persistence can complicate clinical management and potentially worsen the outcome by prolonging the toxic insult.[2] Some of its metabolites have an even longer half-life, recorded at up to 126 hours, further contributing to this issue.[16]

Clinical Applications and Dosing Regimens

The clinical use of Nilutamide is narrowly defined by its approved indication in oncology. While its antiandrogenic properties prompted investigation into other areas, its significant safety concerns have prevented its adoption for any off-label uses.

Approved Indication: Metastatic Prostate Cancer

Nilutamide's sole approved indication is for the treatment of metastatic prostate cancer (Stage D2, characterized by spread to distant lymph nodes, bone, or visceral organs).[4] Crucially, it is indicated for use only in combination with surgical castration (bilateral orchiectomy).[13] This combined approach is a form of Maximal Androgen Blockade (MAB), a therapeutic strategy designed to suppress androgens from all sources. While surgical castration eliminates the production of testosterone from the testes (which accounts for ~90-95% of circulating androgens), the adrenal glands continue to produce androgen precursors. Nilutamide's role is to complement castration by blocking the action of these remaining adrenal androgens at the receptor level, thereby achieving a more complete androgen deprivation.[13]

• Dosing Regimen: For maximum benefit, treatment with Nilutamide must be initiated on the same day as or the day immediately following surgical castration.[5] The standard dosing protocol involves a loading phase followed by a maintenance phase:
• Initial Dose: 300 mg orally once daily for the first 30 days of treatment.
• Maintenance Dose: After the initial 30 days, the dose is reduced to 150 mg orally once daily.[2]
• Clinical Efficacy: The approval of Nilutamide was based on clinical trials demonstrating that the combination of Nilutamide with orchiectomy resulted in a statistically significant improvement in time to disease progression and overall survival time compared to orchiectomy plus a placebo.[16] In addition to its role in MAB, Nilutamide has also been used in the short term to mitigate the effects of the "testosterone flare" that occurs at the beginning of therapy with a gonadotropin-releasing hormone (GnRH) agonist. The initial stimulation of the pituitary by a GnRH agonist causes a transient surge in testosterone before desensitization occurs, and an antiandrogen like Nilutamide can block the effects of this surge.[1]
• Limitations: It is explicitly stated that Nilutamide is not indicated as a monotherapy for the treatment of prostate cancer, as its use alone would lead to a compensatory rise in testosterone levels that would counteract its therapeutic effect.[1]

Investigational and Off-Label Uses

The potent antiandrogenic activity of Nilutamide led to early-phase clinical investigations for other androgen-dependent conditions. However, none of these have translated into approved or recommended clinical practice, primarily due to the drug's unfavorable risk-benefit profile.

• Feminizing Hormone Therapy for Transgender Women: In the late 1980s and early 1990s, before the widespread availability of safer alternatives, Nilutamide was assessed in at least five small clinical studies as a component of feminizing hormone therapy.[1] When used as a monotherapy at a dose of 300 mg/day, it was shown to induce clinical signs of feminization, such as breast development (gynecomastia) and decreased body hair, within 6 to 8 weeks. As predicted by its pharmacodynamics, this monotherapy also led to a significant compensatory increase in LH, testosterone, and estradiol levels. When combined with an estrogen (ethinylestradiol), the increases in LH and testosterone were abolished, while effective antiandrogen action and feminization were maintained.[1] Despite these findings, Nilutamide is not used in modern gender-affirming care. The availability of agents with far superior safety profiles, such as spironolactone and bicalutamide, has rendered its use in this population obsolete.[30]
• Dermatological Conditions (Acne and Seborrhea): Androgens are a key driver of skin conditions like acne and seborrhea. Consequently, Nilutamide was evaluated in at least one small clinical study for the treatment of these conditions in women. At a dose of 200 mg/day, the study reported a "marked decrease" in symptoms within one month and that the conditions "practically disappeared" after two months of treatment.[1] However, official guidance explicitly states that Nilutamide is not approved for nor recommended for use in hyperandrogenic states such as hirsutism or acne due to its potential for serious toxicity.[2]

The historical investigation of Nilutamide for these non-oncologic indications, while ultimately a clinical dead end for the drug itself, was not without value. These early studies provided crucial proof-of-concept that a pure, nonsteroidal androgen receptor antagonist could be an effective therapeutic strategy for conditions like hirsutism, acne, and for use in transgender hormone therapy. This pioneering, albeit flawed, exploration with Nilutamide identified a viable therapeutic pathway. This pathway was later pursued with far greater success by its successor, bicalutamide, which possessed a similar mechanism of action but a vastly improved safety profile. The off-label use of bicalutamide for these very same conditions is now a recognized practice, demonstrating a clear evolutionary line of development where the lessons learned from an older, more toxic agent directly informed the application of a newer, safer one.[30]

Safety Profile and Risk Management

The clinical utility of Nilutamide is fundamentally constrained by its safety profile. Unlike its successors, which are primarily associated with class-effect side effects of androgen deprivation, Nilutamide carries risks of unique, severe, and potentially life-threatening organ toxicities. This high burden of risk necessitates complex monitoring and has been the principal driver of its fall from favor in clinical practice.

Adverse Drug Reactions

Adverse events are very common during Nilutamide therapy, with the overall incidence reported as 86% in patients also undergoing surgical castration and rising to 99.5% in those receiving a concomitant GnRH agonist.[26] Many of the most frequent side effects, such as hot flashes and sexual dysfunction, are consequences of the profound androgen deprivation achieved with combination therapy rather than direct effects of Nilutamide itself.

Adverse Reaction	Incidence with Surgical Castration (%)	Incidence with Leuprolide (GnRH Agonist) (%)
Endocrine
Hot flushes	28	67
Testicular atrophy	N/A	16
Gynecomastia	N/A	11
Libido decreased	N/A	11
Impotence	N/A	11
Special Senses
Impaired adaptation to dark	13	57
Abnormal vision	7	6
Chromatopsia (colored vision)	N/A	9
Gastrointestinal
Nausea	10	24
Constipation	7	20
Abdominal pain	N/A	10
Anorexia	N/A	11
Hepatic
Increased AST	8	13
Increased ALT	8	9
Respiratory
Dyspnea (shortness of breath)	6	11
Nervous System
Dizziness	7	10
Insomnia	N/A	16
Headache	N/A	14
Asthenia (weakness)	N/A	19
General
Pain (general)	N/A	27
Hypertension	5	9
Urinary tract infection	8	9

Table based on data from multicenter clinical trials. "N/A" indicates the adverse event was not reported at an incidence >5% in that specific trial setting..[26]

Serious Warnings and Precautions

The prescribing information for Nilutamide carries prominent warnings for two severe, potentially fatal toxicities.

• Interstitial Pneumonitis: This is the most critical and idiosyncratic adverse reaction associated with Nilutamide.
• Incidence and Risk Factors: In controlled clinical trials involving Western populations, the incidence of interstitial pneumonitis was reported to be approximately 2%.[2] However, there is strong evidence of a significant ethnic predisposition, with studies in patients of Japanese origin reporting a much higher incidence, potentially as high as 13% to 17%.[24]
• Clinical Presentation: The onset is typically acute, occurring within the first three months of initiating therapy. Patients present with symptoms such as new or worsening exertional dyspnea, a persistent dry cough, chest pain, and fever.[5]
• Management and Outcome: Due to the severity of this risk, a baseline chest X-ray is recommended before starting treatment. Patients must be counseled to report any respiratory symptoms immediately. If pneumonitis is suspected, Nilutamide must be discontinued at once pending investigation. While most cases are reversible upon cessation of the drug, there are post-marketing reports of progression to pulmonary fibrosis leading to hospitalization and death.[2]
• Hepatotoxicity: Nilutamide carries a significant risk of liver injury.
• Incidence and Presentation: Mild, asymptomatic elevations in serum aminotransferases (ALT and AST) are common, occurring in up to 33% of patients.[2] Clinically apparent acute liver injury is less common but can be severe, with rare cases of fulminant hepatitis leading to hospitalization or death having been reported.[2] Hepatitis or marked enzyme elevations requiring drug discontinuation occur in approximately 1% of patients.[26] The injury typically manifests within the first 3 to 4 months of treatment and usually presents with a hepatocellular pattern (disproportionate elevation of ALT/AST compared to alkaline phosphatase).[2] Symptoms include nausea, vomiting, right upper quadrant abdominal pain, jaundice, dark urine, and flu-like symptoms.[5]
• Management: Rigorous monitoring of liver function is mandatory. Serum transaminase levels must be measured at baseline, at regular intervals for the first four months of treatment, and periodically thereafter. Liver function tests should also be performed immediately if any signs or symptoms of liver dysfunction appear. Nilutamide should be permanently discontinued if a patient develops jaundice or if ALT levels rise to more than two times the upper limit of normal.[2]

Contraindications and Special Considerations

• Contraindications: Nilutamide is strictly contraindicated in patients with severe pre-existing hepatic impairment, severe respiratory insufficiency, or a known hypersensitivity to the drug or any of its components.[5] It is not for use in women and is absolutely contraindicated during pregnancy.[34]
• Visual Disturbances: A unique and highly characteristic side effect of Nilutamide is a delay in ocular adaptation to darkness, reported in a wide range of 13% to 57% of patients across different studies.[1] Patients experience a prolonged adjustment period, from seconds to minutes, when moving from a well-lit environment to a dark one. This can pose a significant safety risk, particularly when driving at night or through tunnels. Patients must be explicitly cautioned about this effect, which can sometimes be alleviated by wearing tinted glasses.[5]
• Alcohol Intolerance: Approximately 5% to 19% of patients taking Nilutamide experience a disulfiram-like reaction upon ingesting alcohol.[1] This reaction is characterized by facial flushing, malaise, and hypotension. Patients who experience this reaction should be advised to avoid all alcoholic beverages while on treatment.[6]
• Long-Term Risks of Androgen Deprivation: As a component of MAB, Nilutamide contributes to a state of profound androgen deprivation, which carries its own set of long-term health risks. These include an increased risk of bone mineral density loss and osteoporosis, anemia, reduced glucose tolerance potentially leading to diabetes, and adverse effects on cardiovascular risk factors, which may increase the risk of myocardial infarction and stroke.[12]

The safety profile of Nilutamide is not defined by a single major flaw but rather by a collection of unique, clinically significant, and often severe toxicities that create a high cumulative burden of risk. The combination of potentially fatal pulmonary and hepatic events, which require intensive monitoring, with quality-of-life-impacting side effects like visual disturbances and alcohol intolerance, presents a formidable management challenge. When compared to the cleaner profile of bicalutamide—which largely avoids these signature toxicities and is primarily associated with manageable class effects—the risk-benefit calculation for Nilutamide becomes decidedly unfavorable in nearly all clinical scenarios.[3] This multifaceted negative profile is the ultimate reason for its clinical obsolescence.

Drug Interactions

Nilutamide's metabolism via the hepatic CYP450 system makes it susceptible to drug-drug interactions.

• Enzyme Inhibition: In vitro studies have shown that Nilutamide can inhibit the activity of liver microsomal enzymes, particularly CYP2C19 and CYP3A4.[16]
• Clinical Implications: This inhibition can reduce the metabolism of other drugs that are substrates for these enzymes, potentially leading to increased plasma concentrations and an elevated risk of toxicity. Clinically significant interactions have been noted with:
• Warfarin: Increased anticoagulant effect.
• Phenytoin: Increased anticonvulsant levels.
• Theophylline: Increased levels and risk of toxicity.
• Other substrates like propranolol, chlordiazepoxide, and diazepam may also be affected.[10] Close monitoring and dose adjustments of these concomitant medications are necessary.
• QTc Prolongation: Androgen deprivation therapy, including combination therapy with Nilutamide, has been associated with prolongation of the QT interval on an electrocardiogram. Therefore, caution is advised when co-administering Nilutamide with other medications known to prolong the QTc interval, due to the increased risk of Torsades de pointes.[12]

Regulatory History and Therapeutic Context

The trajectory of Nilutamide, from its introduction as an advanced therapeutic option to its current status as a rarely used medication, provides a compelling case study in pharmaceutical evolution. Its history is defined by its relationship to other agents in its class and the shifting standards of care regarding safety and tolerability.

Global Regulatory Status

• Discovery and Initial Approval: Nilutamide was discovered by the French pharmaceutical company Roussel-Uclaf in 1977. It was first introduced for medical use in France in 1987, making it the second nonsteroidal antiandrogen to reach the market after flutamide.[1]
• FDA Approval (United States): The U.S. Food and Drug Administration (FDA) approved the brand name Nilandron (nilutamide) on September 19, 1996, for its specific indication in metastatic prostate cancer.[1] A generic formulation of Nilutamide received FDA approval two decades later, on July 15, 2016.[14]
• TGA Status (Australia): Nilutamide, under the brand name Anandron, was approved for use in Australia, with its availability noted in a 1997 publication.[29] However, reflecting its diminished role in clinical practice, the marketing authorization was formally cancelled by the sponsor, Sanofi-Aventis, on October 7, 2021. As of March 2022, the drug is no longer registered with the Therapeutic Goods Administration (TGA) or listed on the Pharmaceutical Benefits Scheme (PBS), effectively removing it from the Australian market.[41]

This regulatory lifecycle, spanning approval in the mid-1990s to cancellation in major markets in the 2020s, encapsulates the story of a drug rendered obsolete not by a failure of efficacy, but by the emergence of successors with a superior risk-benefit profile. It demonstrates how the standards of acceptable safety and tolerability in medicine evolve over time. A drug once considered a key component of "maximal" therapy can become clinically irrelevant as the pharmaceutical landscape advances, providing a clear lesson in the relentless drive for improved patient outcomes in drug development.

Comparative Analysis with Other First-Generation NSAAs

Nilutamide's place in therapy can only be understood through direct comparison with its first-generation peers, flutamide and bicalutamide. While all three agents are selective androgen receptor antagonists, they possess critical differences in their pharmacological and safety profiles that have dictated their clinical fates.[3] Bicalutamide has emerged as the preferred agent of the class, largely replacing both flutamide and Nilutamide in clinical practice.[3]

The central factors driving this clinical shift are best illustrated through a direct comparison of their key attributes. The following table synthesizes data on dosing, pharmacokinetics, and safety, providing a clear rationale for the ascendancy of bicalutamide and the decline of Nilutamide. This comparative analysis makes it evident that bicalutamide offers the most favorable combination of convenience (once-daily dosing), pharmacological potency (highest AR affinity, longest half-life), and, most importantly, safety, as it avoids the signature severe toxicities associated with both flutamide (diarrhea, high hepatotoxicity risk) and Nilutamide (interstitial pneumonitis, visual disturbances, alcohol intolerance).

Feature	Flutamide	Nilutamide	Bicalutamide
Dosing Frequency	Three times daily	Once daily	Once daily
Elimination Half-Life	~5-9 hours (active metabolite)	~41-49 hours	~6-10 days
Relative AR Affinity	Lower than Bicalutamide	Lower than Bicalutamide	Highest of the three
Signature Adverse Effects	High incidence of diarrhea (~12-20%); High risk of severe hepatotoxicity	Interstitial pneumonitis (~2%); Impaired dark adaptation (13-57%); Alcohol intolerance (~5-19%); Hepatotoxicity	Best tolerated of the three; Lowest risk of hepatotoxicity; No unique severe toxicities

Data compiled from sources.[3]

Expert Synthesis and Conclusion

Nilutamide represents a significant, albeit transitional, chapter in the history of endocrine therapy for prostate cancer. As a first-generation nonsteroidal antiandrogen, it provided a targeted mechanism for blocking the androgen receptor, fulfilling a clear role within the therapeutic strategy of maximal androgen blockade. Its clinical application, however, is narrowly defined by its sole indication for use in combination with surgical castration for metastatic prostate cancer and is profoundly constrained by a significant and unique toxicity profile.

A comprehensive risk-benefit assessment of Nilutamide, particularly in the context of modern therapeutic alternatives, leads to the unequivocal conclusion that its profile is unfavorable. The potential for life-threatening toxicities—namely interstitial pneumonitis and severe hepatitis—imposes a substantial burden of risk and necessitates intensive patient monitoring that is not required for its successors. This risk is compounded by a constellation of common and quality-of-life-impacting side effects, such as the characteristic impairment of dark adaptation and a disulfiram-like intolerance to alcohol, which are not associated with other agents in its class. These considerable drawbacks significantly outweigh the modest efficacy benefits it offers, especially when directly compared to bicalutamide, which provides at least equivalent efficacy with a vastly superior safety and tolerability profile.

From a contemporary clinical standpoint, Nilutamide has been almost entirely superseded by safer, better-tolerated, and more convenient alternatives. Its use today should be restricted to rare and specific circumstances where newer agents are unavailable or strictly contraindicated, and it should only be undertaken with rigorous monitoring and comprehensive patient counseling regarding its unique risks. The trajectory of Nilutamide—from a key component of "maximal" therapy to a therapeutic relic—serves as a powerful illustration of the dynamic nature of pharmaceutical development. It underscores the principle that long-term clinical viability is determined not only by efficacy but, perhaps more critically, by an acceptable balance of safety and tolerability. Nilutamide remains a subject of academic and historical importance, a pharmacological stepping stone that paved the way for the superior androgen receptor antagonists used today.

Works cited

1. Nilutamide - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Nilutamide
2. Nilutamide - LiverTox - NCBI Bookshelf, accessed September 27, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548158/
3. Comparison of bicalutamide with other antiandrogens - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Comparison_of_bicalutamide_with_other_antiandrogens
4. Nilutamide: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed September 27, 2025, https://go.drugbank.com/drugs/DB00665
5. Nilutamide Uses, Side Effects & Warnings - Drugs.com, accessed September 27, 2025, https://www.drugs.com/mtm/nilutamide.html
6. Nilutamide (Nilandron® , Anandron) | OncoLink, accessed September 27, 2025, https://www.oncolink.org/cancer-treatment/oncolink-rx/nilutamide-nilandron-R-anandron
7. Nilutamide (RU-23908, CAS Number: 63612-50-0) | Cayman Chemical, accessed September 27, 2025, https://www.caymanchem.com/product/23953/nilutamide
8. [Nilutamide (200 mg)] - CAS [63612-50-0] - USP Store, accessed September 27, 2025, https://store.usp.org/product/1463472
9. Nilutamide | C12H10F3N3O4 | CID 4493 - PubChem, accessed September 27, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Nilutamide
10. Nilandron (nilutamide) dosing, indications, interactions, adverse ..., accessed September 27, 2025, https://reference.medscape.com/drug/nilandron-nilutamide-342222
11. Nilutamide | CAS 63612-50-0 | RU 23908 | Tocris Bioscience, accessed September 27, 2025, https://www.tocris.com/products/nilutamide_1759
12. niLUTAmide | Cancer Care Ontario, accessed September 27, 2025, https://www.cancercareontario.ca/sites/ccocancercare/files/nilutamide.pdf
13. Nilandron Prescribing Information - sanofi-aventis U.S. LLC, accessed September 27, 2025, https://products.sanofi.us/nilandron/nilandron.html
14. Nilutamide Tablets, 150 mg - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/207631Orig1s000.pdf
15. Nilutamide 63612-50-0 | TCI AMERICA - TCI Chemicals, accessed September 27, 2025, https://www.tcichemicals.com/US/en/p/N1212
16. NILANDRON® (nilutamide tablets) - Sanofi U.S., accessed September 27, 2025, https://products.sanofi.us/nilandron/nilandron.pdf
17. Nilutamide (CAS 63612-50-0) - R&D Systems, accessed September 27, 2025, https://www.rndsystems.com/products/nilutamide_1759
18. go.drugbank.com, accessed September 27, 2025, https://go.drugbank.com/drugs/DB00665#:~:text=Nilutamide%20is%20a%20pure%2C%20nonsteroidal,normal%20and%20malignant%20prostatic%20tissue.
19. Nilutamide | Davis's Drug Guide for Rehabilitation Professionals, accessed September 27, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139019865
20. What is the mechanism of Nilutamide? - Patsnap Synapse, accessed September 27, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-nilutamide
21. What is Nilutamide used for? - Patsnap Synapse, accessed September 27, 2025, https://synapse.patsnap.com/article/what-is-nilutamide-used-for
22. Definition of nilutamide - NCI Drug Dictionary, accessed September 27, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nilutamide
23. Receptor affinity and potency of non-steroidal antiandrogens: translation of preclinical findings into clinical activity - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/12496872/
24. niLUTAmide - Cancer Care Ontario, accessed September 27, 2025, https://www.cancercareontario.ca/en/drugformulary/drugs/monograph/43816
25. Flutamide vs. Nilutamide for Prostate Cancer: Important Differences and Potential Risks. - GoodRx, accessed September 27, 2025, https://www.goodrx.com/compare/flutamide-vs-nilutamide
26. Nilutamide Tablets Rx Only 9625 Rev 12/15 ... - accessdata.fda.gov, accessed September 27, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/207631Orig1s000lbl.pdf
27. Nilutamide - NCI, accessed September 27, 2025, https://www.cancer.gov/about-cancer/treatment/drugs/nilutamide
28. Nilutamide (oral route) - Side effects & dosage - Mayo Clinic, accessed September 27, 2025, https://www.mayoclinic.org/drugs-supplements/nilutamide-oral-route/description/drg-20072510
29. Nilutamide - Australian Prescriber - Therapeutic Guidelines, accessed September 27, 2025, https://australianprescriber.tg.org.au/articles/nilutamide.html
30. Bicalutamide and its Adoption by the Medical Community for Use in Transfeminine Hormone Therapy, accessed September 27, 2025, https://transfemscience.org/articles/bica-adoption/
31. Antiandrogens - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/31643810/
32. Medical uses of bicalutamide - Wikipedia, accessed September 27, 2025, https://en.wikipedia.org/wiki/Medical_uses_of_bicalutamide
33. Bicalutamide: A review - PMC - PubMed Central, accessed September 27, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11980709/
34. Nilutamide: MedlinePlus Drug Information, accessed September 27, 2025, https://medlineplus.gov/druginfo/meds/a697044.html
35. Nilutamide (Nilandron® , Anandron) - Perelman School of Medicine at the University of Pennsylvania, accessed September 27, 2025, https://www.med.upenn.edu/prostate2022/assets/user-content/documents/nilutamide-nilandron-anandron-eng-us.pdf
36. Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/10388026/
37. Nilutamide – Knowledge and References - Taylor & Francis, accessed September 27, 2025, https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Pharmaceutical_medicine/Nilutamide/
38. Generic Nilandron Availability - Drugs.com, accessed September 27, 2025, https://www.drugs.com/availability/generic-nilandron.html
39. Nilutamide - CanMED: HCPCS - SEER - National Cancer Institute, accessed September 27, 2025, https://seer.cancer.gov/oncologytoolbox/canmed/hcpcs/1335/
40. FDA approves first generic nilutamide for treatment of prostate cancer, accessed September 27, 2025, https://www.gabionline.net/generics/news/FDA-approves-first-generic-nilutamide-for-treatment-of-prostate-cancer
41. ANANDRON nilutamide 150mg tablet blister pack Cancelled under Section 30(1)(c) of the Act | Therapeutic Goods Administration (TGA), accessed September 27, 2025, https://www.tga.gov.au/resources/cancellations-by-sponsors/anandron-nilutamide-150mg-tablet-blister-pack-cancelled-under-section-301c-act
42. 1478-Prostate metastatic nilutamide DISCONTINUED - eviQ, accessed September 27, 2025, https://www.eviq.org.au/medical-oncology/urogenital/prostate/1478-prostate-metastatic-nilutamide-discontinued
43. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first - PubMed, accessed September 27, 2025, https://pubmed.ncbi.nlm.nih.gov/10587288/